Nektar Therapeutics (NKTR) Stock: What Does the Chart Say Tuesday?

Overall market sentiment has been down on Nektar Therapeutics (NKTR) stock lately. NKTR receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Nektar Therapeutics has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on NKTR!

See Full NKTR Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With NKTR Stock Today?

Nektar Therapeutics (NKTR) stock is trading at $16.59 as of 1:46 PM on Tuesday, Oct 19, an increase of $0.25, or 1.56% from the previous closing price of $16.33. The stock has traded between $16.23 and $16.68 so far today. Volume today is 761,364 compared to average volume of 914,940. To see InvestorsObserver's Sentiment Score for Nektar Therapeutics click here.

More About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. The company has additional operations facilities in Huntsville, Alabama, and Hyderabad, India. Click Here to get the full Stock Report for Nektar Therapeutics stock.